Medherant Revenue and Competitors

Medherant is a clinical stage drug delivery company developing products for pain and CNS diseases. The Company was founded by Professor David Haddleton and the University of Warwick in 2015 based on their world-leading expertise in bioadhesives and polymer chemistry. Medherant has developed a novel drug-in-adhesive transdermal delivery system, the TEPI® Patch, using a proprietary adhesive which it has exclusively licensed from Bostik. The adhesive has a high drug loading capacity, so a smaller quantity of adhesive is needed to deliver a therapeutic dose; the patch can therefore be thinner and more flexible. It also enables excipients, such as permeation enhancers, to be included in the adhesive so the release of the drug from the patch can be tailored to achieve the desired product profile. The adhesive also provides excellent adhesion, even in moist conditions. This means that the patch remains in contact with the skin throughout the dosing period, so the full dose is delivered. There is no leakage of adhesive from the patch so there is no unsightly black ring around its edge and no residue on the skin after removal. Medherant has a portfolio of five products, the most advanced of which is its Ibuprofen TEPI Patch, the safety of which has been demonstrated in Phase I clinical studies. The other products are a cannabinoid, an opioid, and two drugs to treat Alzheimer's disease. The Company also undertakes feasibility studies for other companies to investigate whether their drugs can be formulated for transdermal delivery using the TEPI technology. Medherant welcomes enquires from companies interested in licensing its products for commercialisation or undertaking feasibility studies.